Li Lu, Huang Yecai, Yin Jun, Xu Peng, Lan Mei, Li Churong, Qi Yunxiang, Xu Ke, Li Bosen, Luo Yukun, Jiang Qinghua, Peng Shanshan, Lang Jinyi, Feng Mei
Department of Radiation Oncology, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China.
The Third People's Hospital of Sichuan Province, Chengdu, China.
Integr Cancer Ther. 2025 Jan-Dec;24:15347354251314499. doi: 10.1177/15347354251314499.
Radiotherapy-induced oral mucositis is the most common side effect in nasopharyngeal carcinoma (NPC) patients. We aimed to evaluate the efficacy and safety of Rabdosia rubescens drop pills in NPC patients with radiation-induced oral mucositis (RTOM).
The study involved 40 NPC patients who were given Rabdosia rubescens drop pills thrice daily from the start of radiation therapy. The study monitored the incidence and severity of oral mucositis and oral pain. The main outcomes measured were the occurrence rate of oral mucositis, grade 3 oral mucositis, oral pain assessment, and changes in immunological function, body weight, BMI, NRS2002, and albumin levels.
In the study, 38 patients completed the treatment. The incidence rates of Grade 0 to 3 oral mucositis were 5.26%, 21.05%, 47.37%, and 26.32% respectively. Pain levels were mild (42.11%), moderate (13.16%), and severe (13.16%). The onset of Grade 1, 2, and 3 oral mucositis occurred at 18, 24, and 30 days respectively. Grade 3 oral mucositis was associated with body weight, BMI, NRS2002 score, and albumin levels. Post-treatment, there was a decrease in CD4/CD8, CD3, and CD4 immune cells, but an increase in CD8 cells. Mild to moderate gastrointestinal adverse events were observed in 13.2% of patients.
Rabdosia rubescens drop pills administration can reduce the incidence and severity of radiotherapy induced oral mucositis. Our finding suggested a positive impact of Rabdosia rubescens drops pills upon administration to NPC patients.
放疗引起的口腔黏膜炎是鼻咽癌（NPC）患者最常见的副作用。我们旨在评估冬凌草滴丸对鼻咽癌放疗所致口腔黏膜炎（RTOM）患者的疗效和安全性。
本研究纳入40例NPC患者，从放疗开始每日三次给予冬凌草滴丸。研究监测口腔黏膜炎和口腔疼痛的发生率及严重程度。主要测量指标为口腔黏膜炎的发生率、3级口腔黏膜炎、口腔疼痛评估以及免疫功能、体重、BMI、NRS2002和白蛋白水平的变化。
本研究中，38例患者完成治疗。0至3级口腔黏膜炎的发生率分别为5.26%、21.05%、47.37%和26.32%。疼痛程度为轻度（42.11%）、中度（13.16%）和重度（13.16%）。1、2和3级口腔黏膜炎的发病时间分别为18、24和30天。3级口腔黏膜炎与体重、BMI、NRS2002评分和白蛋白水平相关。治疗后，CD4/CD8、CD3和CD4免疫细胞减少，但CD8细胞增加。13.2%的患者出现轻度至中度胃肠道不良事件。
服用冬凌草滴丸可降低放疗引起的口腔黏膜炎的发生率和严重程度。我们的研究结果表明，冬凌草滴丸对鼻咽癌患者给药有积极影响。
